Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulahannan, Susanna V, Brahmer, Julie R
Formato: Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082199/
https://www.ncbi.nlm.nih.gov/pubmed/21469981
http://dx.doi.org/10.3109/07357907.2011.554476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082199/
https://www.ncbi.nlm.nih.gov/pubmed/21469981
http://dx.doi.org/10.3109/07357907.2011.554476

Ejemplares similares